# A Study of TG103 Injection in Type 2 Diabetes Subjects

Study · id `cardio:ct-nct05348122` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05348122](<https://clinicaltrials.gov/study/NCT05348122>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05348122

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT05348122. Randomized; single masking; primary purpose treatment. Start 2022-06-15 (anticipated); primary completion 2023-11-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT05348122, source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)
- Planned start: 2022-06-15 (anticipated) (ClinicalTrials.gov record NCT05348122, source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)
- Primary completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT05348122, source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)
- Completion: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT05348122, source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05348122, source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05348122-2022-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of TG103 Injection in Type 2 Diabetes Subjects
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): TG103,Q2W
- Intervention (Drug): TG103,QW
- Intervention (Drug): Placebo,Q2W
- Intervention (Drug): Placebo,QW
- Intervention (Drug): Dulaglutide,QW
- Lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (`cardio:org-cspc-baike-shandong-biopharmaceutical-co-ltd`)

## Provenance

Content hash: c68431633972f330d25e44f08e0950c2882844c959d345b250b9cade81cac85f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
